Skip to main content
LaSonji A. Holman on Muck Rack

LaSonji A. Holman

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with LaSonji A.

Contact LaSonji A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial

|
By Aurélie Ploquin, Rosemarie Mason, Myra Happe, Alicia Widge, Laura Novik, Ana M. Ortega-Villa, Galina V. Yamshchikov, Ingelise Gordon, Abidemi Ola, Anita Arthur, Floreliz Mendoza, Jamie Saunders, William Whalen, Joanna Utoh, Jennifer Cunningham Verified, Lorin N. Loftus, Ashley Heimann, Katia G. Korzeniwsky, Shayne F. Andrew, Evan R. Lamb, Amelia Thompson, Mary McDonald, Kathryn E. Foulds, Nancy Sullivan, Emily Coates, Rebecca J. Loomis, Barney S. Graham, Karin Bok, Sunny Himansu, Brett Leav, John H Beigel, Mario Roederer, Lesia Dropulic, LaSonji A. Holman, Pamela J. M. Costner, Xioalin Wang, Shruthi Shyam Sunder, Jessica Bahorich, Walla Dempsey
| Nature Verified
Abstract Nipah virus (NiV) is a highly pathogenic, zoonotic paramyxovirus with pandemic potential. No licensed vaccines or treatments are available. Therefore, we conducted a phase 1, first-in-human, open-label, dose-escalation trial of a lipid nanoparticle mRNA vaccine, mRNA-1215, encoding a chimeric pre-fusion F (Pre-F) protein linked to glycoprotein G of a NiV Malaysian strain.
Open in Who Shared Issue with article?
See all 1 articles